Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL8805297 | 1.00 | — | — | |
| Methylene Chloride SCHEMBL3432012 | 1.00 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1ALOX15HIF1A | |
| Methylene Chloride SCHEMBL2207208 | 1.00 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1ALOX15HIF1A | |
| Methylene Chloride SCHEMBL7701261 | 1.00 | CYP3A4 (0.35) | CYP3A4TSHRALDH1A1ALOX15HIF1A | |
| Water SCHEMBL16146969 | 0.93 | — | — | |
| SCHEMBL141108 | 0.93 | — | — | |
| Acetonitrile SCHEMBL4028413 | 0.84 | — | — | |
| Methyl Alcohol SCHEMBL3490957 | 0.84 | — | — | |
| Acetonitrile SCHEMBL8026268 | 0.84 | TSHR (0.32) | CYP3A4TSHRALDH1A1ALOX15HIF1A | |
| Acetone SCHEMBL4628352 | 0.77 | MCL1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620820-B2 | Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | disclosed |
| US-6492356-B1 | Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-10 | — | — | US | disclosed |
| EP-1042301-B1 | NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA GMBH (DE) | 2002-11-20 | — | — | EP | disclosed |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | HOECHST AKTIENGESELLSCHAFT | 2002-08-29 | — | — | US | disclosed |
| US-6218415-B1 | THERAPY OF BONE REABSORPTION BY OSTEOCLASTS, TUMOR GROWTH AND TUMOR METASTASIS, INFLAMMATION, CARDIOVASCULAR DISEASE, NEPHROPATHIES AND RETINOPATHIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
| EP-1042301-A1 | NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| EP-0933367-A1 | Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-08-04 | — | — | EP | disclosed |
| WO-1999032457-A1 | NOVEL ACYLGUANIDINE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | CYP3A4 3967/4885TSHR 631/4885ALDH1A1 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.